Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Mallinckrodt
Moodys
Johnson and Johnson
Express Scripts

Last Updated: March 27, 2023

Investigational Drug Information for Tegafur


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug Tegafur?

Tegafur is an investigational drug.

There have been 147 clinical trials for Tegafur. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2013.

The most common disease conditions in clinical trials are Stomach Neoplasms, Colorectal Neoplasms, and Pancreatic Neoplasms. The leading clinical trial sponsors are Fudan University, Taiho Pharmaceutical Co., Ltd., and National Cancer Institute (NCI).

There is one US patent protecting this investigational drug and twenty-eight international patents.

Recent Clinical Trials for Tegafur
TitleSponsorPhase
Conversion Therapy of Disitamab Vedotin Combined With Sintilimab and S-1 in HER2 Overexpression Gastric CancerTianjin Medical University Cancer Institute and HospitalPhase 2
A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma.Innovent Biologics (Suzhou) Co. Ltd.Phase 2
A Biomarker Study for Predicting the Efficacy of Neoadjuvant Sintilimab Plus SOX for Gastric Adenocarcinoma.Nanjing Geneseeq Technology IncPhase 2

See all Tegafur clinical trials

Clinical Trial Summary for Tegafur

Top disease conditions for Tegafur
Top clinical trial sponsors for Tegafur

See all Tegafur clinical trials

US Patents for Tegafur

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tegafur See Plans and Pricing Heterocyclic compound Takeda Pharmaceutical Company Limited (Osaka, JP) See Plans and Pricing
Tegafur See Plans and Pricing Chimeric polypeptides, polynucleotides encoding same, cells expressing same and methods of producing same Protalix Ltd. (Carmiel, IL) See Plans and Pricing
Tegafur See Plans and Pricing Nuclear targeting sequences Yeda Research and Development Co. Ltd. (Rehovot, IL) See Plans and Pricing
Tegafur See Plans and Pricing Method of diagnosing and treating cancer using B-catenin splice variants The United States of America, as represented by the Secretary, Department of Health & Human Services (Washington, DC) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Tegafur

Drugname Country Document Number Estimated Expiration Related US Patent
Tegafur Canada CA2961033 2034-09-11 See Plans and Pricing
Tegafur European Patent Office EP3192791 2034-09-11 See Plans and Pricing
Tegafur Japan JPWO2016039408 2034-09-11 See Plans and Pricing
Tegafur World Intellectual Property Organization (WIPO) WO2016039408 2034-09-11 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Mallinckrodt
Moodys
Johnson and Johnson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.